These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30213508)

  • 1. Patients with Peripheral Artery Disease in the COMPASS Trial.
    Kruger PC; Anand SS; de Vries TAC; Eikelboom JW
    Eur J Vasc Endovasc Surg; 2018 Dec; 56(6):772-773. PubMed ID: 30213508
    [No Abstract]   [Full Text] [Related]  

  • 2. Rivaroxaban (Xarelto) plus aspirin for secondary prevention of cardiovascular events.
    Med Lett Drugs Ther; 2018 Dec; 60(1561):196-197. PubMed ID: 30653475
    [No Abstract]   [Full Text] [Related]  

  • 3. Will COMPASS Point to a New Direction in Thrombotic Risk Reduction in Patients With Stable Cardiovascular Disease?
    Boden WE; Bhatt DL
    Circulation; 2018 Aug; 138(9):858-860. PubMed ID: 30354448
    [No Abstract]   [Full Text] [Related]  

  • 4. Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial.
    Nicholls SJ; Nelson AJ
    Am J Cardiovasc Drugs; 2019 Aug; 19(4):343-348. PubMed ID: 30680652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease.
    Liang Y; Zhu J; Liu L; Anand SS; Connolly SJ; Bosch J; Guzik TJ; O'Donnell M; Dagenais GR; Fox KA; Shestakovska O; Berkowitz SD; Muehlhofer E; Keller L; Yusuf S; Eikelboom JW;
    Cardiovasc Res; 2021 Feb; 117(3):942-949. PubMed ID: 32289159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial.
    Fox KAA; Eikelboom JW; Shestakovska O; Connolly SJ; Metsarinne KP; Yusuf S
    J Am Coll Cardiol; 2019 May; 73(18):2243-2250. PubMed ID: 31072566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease: COMPASS in context.
    Patrono C
    Cardiovasc Res; 2017 Dec; 113(14):e61-e63. PubMed ID: 29186439
    [No Abstract]   [Full Text] [Related]  

  • 8. Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
    Coppens M; Weitz JI; Eikelboom JWA
    Circ Res; 2019 Feb; 124(3):416-425. PubMed ID: 30702997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin.
    Eikelboom JW; Bosch JJ; Connolly SJ; Shestakovska O; Dagenais GR; Hart RG; Leong DP; O'Donnell M; Fox KAA; Bhatt DL; Cairns JA; Tasto C; Berkowitz SD; Cook Bruns N; Muehlhofer E; Diaz R; Maggioni AP; Yusuf S
    J Am Coll Cardiol; 2019 Sep; 74(12):1519-1528. PubMed ID: 31537259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease.
    Branch KR; Probstfield JL; Eikelboom JW; Bosch J; Maggioni AP; Cheng RK; Bhatt DL; Avezum A; Fox KAA; Connolly SJ; Shestakovska O; Yusuf S
    Circulation; 2019 Aug; 140(7):529-537. PubMed ID: 31163978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban versus Clopidogrel for Peripheral Artery Disease: A Clinico-Economic Approach of the COMPASS Trial.
    Tsilimigras DI; Moris D; Karaolanis G; Kakkos SK; Filis K; Sigala F
    Curr Pharm Des; 2018; 24(38):4516-4517. PubMed ID: 30621559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial.
    Anand SS; Caron F; Eikelboom JW; Bosch J; Dyal L; Aboyans V; Abola MT; Branch KRH; Keltai K; Bhatt DL; Verhamme P; Fox KAA; Cook-Bruns N; Lanius V; Connolly SJ; Yusuf S
    J Am Coll Cardiol; 2018 May; 71(20):2306-2315. PubMed ID: 29540326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial.
    Vanassche T; Verhamme P; Anand SS; Shestakovska O; Fox KA; Bhatt DL; Avezum A; Alings M; Aboyans V; Maggioni AP; Widimsky P; Berkowitz SD; Yusuf S; Connolly SJ; Eikelboom JW; Bosch J
    Eur J Prev Cardiol; 2020 Feb; 27(3):296-307. PubMed ID: 31615291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice-Insights From the CANHEART Study.
    Sheth MS; Yu B; Chu A; Porter J; Tam DY; Ferreira-Legere LE; Goodman SG; Farkouh ME; Ko DT; Abdel-Qadir H; Udell JA
    J Am Heart Assoc; 2022 Dec; 11(24):e026553. PubMed ID: 36515238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence.
    Weitz JI; Angiolillo DJ; Geisler T; Heitmeier S
    Thromb Haemost; 2020 Aug; 120(8):1147-1158. PubMed ID: 32594508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivaroxaban in peripheral artery disease: The new kid on the block?
    Hussain MA; Verma S; Al-Omran M
    J Vasc Surg; 2018 Mar; 67(3):985-986. PubMed ID: 29477208
    [No Abstract]   [Full Text] [Related]  

  • 17. Role of rivaroxaban in the prevention of atherosclerotic events.
    Sanmartín M; Bellmunt S; Cosín-Sales J; García-Moll X; Riera-Mestre A; Almendro-Delia M; Hernández JL; Lozano F; Mazón P; Suarez Fernández C
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):771-780. PubMed ID: 31269825
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
    Moayyedi P; Eikelboom JW; Bosch J; Connolly SJ; Dyal L; Shestakovska O; Leong D; Anand SS; Störk S; Branch KRH; Bhatt DL; Verhamme PB; O'Donnell M; Maggioni AP; Lonn EM; Piegas LS; Ertl G; Keltai M; Bruns NC; Muehlhofer E; Dagenais GR; Kim JH; Hori M; Steg PG; Hart RG; Diaz R; Alings M; Widimsky P; Avezum A; Probstfield J; Zhu J; Liang Y; Lopez-Jaramillo P; Kakkar AK; Parkhomenko AN; Ryden L; Pogosova N; Dans AL; Lanas F; Commerford PJ; Torp-Pedersen C; Guzik TJ; Vinereanu D; Tonkin AM; Lewis BS; Felix C; Yusoff K; Metsarinne KP; Fox KAA; Yusuf S;
    Gastroenterology; 2019 Sep; 157(3):682-691.e2. PubMed ID: 31152740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease.
    Eikelboom JW; Bhatt DL; Fox KAA; Bosch J; Connolly SJ; Anand SS; Avezum A; Berkowitz SD; Branch KRH; Dagenais GR; Félix C; Guzik TJ; Hart RG; Maggioni AP; Muehlhofer E; Sharma M; Shestakovska O; Yusuf S
    J Am Coll Cardiol; 2021 Jul; 78(1):14-23. PubMed ID: 34210409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolving treatment of peripheral arterial disease: preventing ischaemic events in the post-COMPASS era.
    Kaplovitch E; Anand SS
    Cardiovasc Res; 2019 Oct; 115(12):e121-e124. PubMed ID: 31321405
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.